Unlock instant, AI-driven research and patent intelligence for your innovation.

Improved treatment of renal cell carcinoma

A renal cell carcinoma, cytotoxic technology, applied in the field of cancer treatment, can solve problems such as tissue damage, achieve the effect of improving quality of life, reducing stress, and avoiding dialysis treatment

Active Publication Date: 2013-03-20
ONCORENA
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, despite Orellanine's apparent specificity, there may be collateral damage to other tissues when it is used for RCC therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improved treatment of renal cell carcinoma
  • Improved treatment of renal cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Synthesis of Orellanine

[0113] Orellanine was synthesized from commercially available 3-hydroxypyridine essentially as described by others. (Tiecco M, Tingoli M, Testaferri L, Chianelli D and Wenkert E: Total synthesis of Orellanine, the lethal toxin of Cortinarius orellanus Fries Mushroom. Tetrahedron 42, 1475-1485(1986).

Embodiment 2

[0115] Orellanine conjugated to polyethylene glycol (PEG)

[0116] A. Conjugate on carbon

[0117] A solution of lithium diisopropylamide (LDA) was prepared at -23°C from diisopropylamine (0.77ml, 5.50mmol) and 1.55M n-butyllithium (3.55ml, 5.50mmol) in 10ml tetrahydrofuran (THF). After 15 minutes, 3,3',4,4'-tetramethoxy-2,2'-bipyridine-bis-N-oxide (1.54 g, 5.00 mmol) was added and the resulting mixture was stirred at -23°C 30 minutes. 1-Bromo-2-(2-methoxyethoxy)ethane (1.19 g, 6.50 mmol) was added and the reaction mixture was stirred at -23°C for 15 minutes and at room temperature for 1 hour. Water (10ml) and diethyl ether (10ml) were added and the layers were separated. The aqueous phase was extracted with diethyl ether (3 x 25ml). The combined organic extracts were washed with 25ml portions of water and brine. in anhydrous Na 2 SO 4 After drying, the solvent was removed in vacuo to give the crude product. By flash chromatography (SiO 2 , 25% EtOAc in hexanes) aff...

Embodiment 3

[0125] Label Orellanine with Astatine 211 (At-211)

[0126] 13 mg, 0.051 mmol Orellanine and 32.8 mg of 0.3 mmol sodium carbonate were dissolved in 1.2 ml of water. lodoGen beads (Thermo Fisher Scientific, Rockford, IL) were added followed by 0.20 mmol of radioactive iodine in the form of NaI. The mixture was stirred at room temperature for 90 minutes. The mixture was then filtered to remove the lodoGen beads, and the filtrate was washed with 42 mg NaHSO 4 acidification. Labeled Orellanine was isolated by preparative HPLC.

[0127] Similarly, preparations produced by irradiating native Bi with 28 MeV α particles, with 211 At radiohalogenated orellanine derivatives, purified by distillation, collected in Teflon tubes. Except for Orellanine synthesized according to Example 1, all standard chemicals were purchased from local merchants.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for treating renal cancer by administration of certain 3,3',4,4'-tetrahydroxy-2,2'- bipyridine-N,N'-dioxide compounds, especially 3,3',4,4'-tetrahydroxy-2,2'-bipyridine-N,N'- dioxide (Orellanine), conjugated to an alpha-emitting radionuclide (e.g. Astatine-211) to increase the efficacy of the formulation and / or a large molecule (e.g. a oligomer / polymer such as a PEG or a polysaccharide such as a dextran or a Ficoll TM ) to reduce the filtration and consequently the renal exposure. Particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods can be used.

Description

technical field [0001] The present invention relates generally to cancer treatment. More specifically, the present invention relates to α-emitting radionuclides (such as astatine 211) or macromolecules (such as PEG, dextran or FICOLL ) conjugated 3,3',4,4'-tetrahydroxy-2,2'-dipyridine-N,N'-dioxide, especially 3,3',4,4'-tetrahydroxy-2 , 2'-dipyridine-N,N'-dioxide (Orellanine) for the therapeutic use of kidney cancer, especially renal cell carcinoma originating from proximal renal tubular cells. Background technique [0002] Cancer occurs in more than 100 different forms and affects nearly every part of the body. Throughout life, healthy cells in the body divide, grow and replace themselves in a controlled manner. Cancer develops when the genes that instruct this cell division to malfunction and cells begin to multiply and grow uncontrollably. These clumps or clusters of abnormal cells are called tumors. Not all tumors are cancerous. Benign tumors, such as moles, stop g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/444A61K47/30A61K51/04A61P35/00A61K31/4427A61P13/12A61P35/04A61K101/02A61K39/00
CPCA61K47/48A61K39/00A61K47/4823A61K31/765A61K51/08A61K51/0497A61K45/06A61K35/74A61K47/48215A61K51/065A61K31/444A61K47/60A61K47/61A61K2039/5158A61K2039/55522A61P13/12A61P35/00A61P35/04A61P43/00A61K2300/00A61K31/4427A61K51/04
Inventor 伯耶·哈拉尔德松乌尔夫·尼尔松莉萨·布瓦尔燕妮·尼斯特伦
Owner ONCORENA